Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,